Within the brain, these cytokines may impair neuronal connectivity and plasticity, contributing to the cognitive and behavioral changes commonly observed in DS [188]
[] Several pieces of evidence suggested GLP-1 can enter into CNS by crossing the tight endothelial junction of bloodbrain barrier (BBB) administered peripherally through various routes
Good Manufacturing Practice applies to the entire drug manufacturing process while Good Laboratory Practice applies only to the safety testing phase
Yes for most clients
Very common side effects (affecting more than 1 in 10 people) include: Nausea, vomiting, and diarrhoea (usually temporary) Reduced appetite Common side effects (affecting up to 1 in 10 people) include: Constipation Abdominal pain or discomfort Headache Injection site reactions Fatigue Contact your GP promptly if you experience: Persistent or severe abdominal pain , particularly if radiating to the backthis may indicate pancreatitis Persistent vomiting that prevents adequate fluid intake Signs of dehydration : reduced urination, dizziness, dry mouth Symptoms of hypoglycaemia (if taking alongside insulin or sulphonylureas): trembling, sweating, confusion, rapid heartbeat Visual changes or eye pain, especially if you have diabetic retinopathy Unexplained weight loss exceeding expected therapeutic effect Mood changes or thoughts of self-harm Right upper abdominal pain, yellowing of skin/eyes, or dark urine which may indicate gallbladder problems Seek immediate medical attention (call 999 or attend A&E) if you develop: Severe, persistent abdominal pain with vomiting Signs of severe allergic reaction: difficulty breathing, facial swelling, severe rash Symptoms of diabetic ketoacidosis (particularly if insulin doses have been reduced): excessive thirst, frequent urination, confusion, fruity breath odour Severe hypoglycaemia with loss of consciousness Important safety information: GLP-1 medications are not recommended during pregnancy or breastfeeding
The shielding action of GLP-1 also involves the activation of the phosphoinositide 3-kinase (PI3K) and extracellular signal-regulated kinase (ERK) pathways and the upregulation of PDX-1 transcription (36)
